US Edition
Traws Pharma Surges Premarket on Bird Flu Cure Momentum – Own Snap
Summary by ownsnap.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Traws Pharma Surges Premarket on Bird Flu Cure Momentum – Own Snap
TRAW stock is turning heads today, with shares soaring to $3.41 in premarket trading = a massive 70.5% jump from yesterday’s $2.00 close. The buzz? It’s all about their promising bird flu treatment, tivoxavir marboxil. On March 3, 2025, Traws announced breakthrough results from a study using ferrets, a common model for human flu research. Just one oral dose of tivoxavir dramatically slowed the progression of H5N1 infection, suggesting real poten…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
